TH
Therapeutic Areas
Artiva Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AlloNK + Rituximab | Refractory Rheumatoid Arthritis, Sjögren’s Disease, Idiopathic Inflammatory Myopathies, Systemic Sclerosis | Phase 1/2 |
| AlloNK + Rituximab (IIT) | Rheumatoid Arthritis, Pemphigus Vulgaris, ANCA-Associated Vasculitis, Systemic Lupus Erythematosus | Phase 1/2 |
| AlloNK + Obinutuzumab | Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1/2 |
| CAR-NK (AB-205) | CD5+ Hematologic Malignancies | Preclinical |
| CAR-NK (AB-201) | HER2+ Solid Tumors | Preclinical |
Leadership Team at Artiva Biotherapeutics
FA
Fred Aslan, M.D.
President and Chief Executive Officer
SB
Subhashis Banerjee, M.D.
Chief Medical Officer
JB
Jennifer Bush
Chief Operating Officer
CH
Christopher Horan
Chief Technical Operations Officer
BD
Benjamin Dewees
SVP, Regulatory Affairs
DM
David Moriarty, Ph.D.
SVP, Clinical Operations
HR
Heather Raymon, Ph.D.
SVP, Research & Early Development
FX
Feng Xu
SVP, Biometrics
AC
Andrew Cronauer
VP, General Counsel & Corporate Secretary
SM
Sara Mills
VP, Regulatory Affairs, CMC